Global Biologics and Biosimilars 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI01242719

Publication Date:

January 4, 2024

Pages:

147

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Biologics and Biosimilars market size was valued at US$ 458090 million in 2023. With growing demand in downstream market, the Biologics and Biosimilars is forecast to a readjusted size of US$ 837640 million by 2030 with a CAGR of 9.0% during review period.
The research report highlights the growth potential of the global Biologics and Biosimilars market. Biologics and Biosimilars are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Biologics and Biosimilars. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Biologics and Biosimilars market.
Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the largest manufacturer being Pfizer with over 20% share. In terms of product categories, monoclonal antibodies are the largest segment with a market share of 43%, followed by vaccines with a 30% share. In terms of applications, hospitals are the top application area, with about 85% of the market share.
Key Features:
The report on Biologics and Biosimilars market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Biologics and Biosimilars market. It may include historical data, market segmentation by Type (e.g., Monoclonal Antibodies, Interferon), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Biologics and Biosimilars market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Biologics and Biosimilars market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Biologics and Biosimilars industry. This include advancements in Biologics and Biosimilars technology, Biologics and Biosimilars new entrants, Biologics and Biosimilars new investment, and other innovations that are shaping the future of Biologics and Biosimilars.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Biologics and Biosimilars market. It includes factors influencing customer ' purchasing decisions, preferences for Biologics and Biosimilars product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Biologics and Biosimilars market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Biologics and Biosimilars market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Biologics and Biosimilars market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Biologics and Biosimilars industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Biologics and Biosimilars market.
麻豆原创 Segmentation:
Biologics and Biosimilars market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Segmentation by application
Hospital
Retail Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Biologics and Biosimilars 麻豆原创 Size 2019-2030
2.1.2 Biologics and Biosimilars 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Biologics and Biosimilars Segment by Type
2.2.1 Monoclonal Antibodies
2.2.2 Interferon
2.2.3 Insulin
2.2.4 Vaccines
2.2.5 Others
2.3 Biologics and Biosimilars 麻豆原创 Size by Type
2.3.1 Biologics and Biosimilars 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Biologics and Biosimilars 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Biologics and Biosimilars Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Other
2.5 Biologics and Biosimilars 麻豆原创 Size by Application
2.5.1 Biologics and Biosimilars 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Biologics and Biosimilars 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Biologics and Biosimilars 麻豆原创 Size by Player
3.1 Biologics and Biosimilars 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Biologics and Biosimilars Revenue by Players (2019-2024)
3.1.2 Global Biologics and Biosimilars Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Biologics and Biosimilars Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Biologics and Biosimilars by Regions
4.1 Biologics and Biosimilars 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Biologics and Biosimilars 麻豆原创 Size Growth (2019-2024)
4.3 APAC Biologics and Biosimilars 麻豆原创 Size Growth (2019-2024)
4.4 Europe Biologics and Biosimilars 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Biologics and Biosimilars 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Biologics and Biosimilars 麻豆原创 Size by Country (2019-2024)
5.2 Americas Biologics and Biosimilars 麻豆原创 Size by Type (2019-2024)
5.3 Americas Biologics and Biosimilars 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biologics and Biosimilars 麻豆原创 Size by Region (2019-2024)
6.2 APAC Biologics and Biosimilars 麻豆原创 Size by Type (2019-2024)
6.3 APAC Biologics and Biosimilars 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Biologics and Biosimilars by Country (2019-2024)
7.2 Europe Biologics and Biosimilars 麻豆原创 Size by Type (2019-2024)
7.3 Europe Biologics and Biosimilars 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Biologics and Biosimilars by Region (2019-2024)
8.2 Middle East & Africa Biologics and Biosimilars 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Biologics and Biosimilars 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Biologics and Biosimilars 麻豆原创 Forecast
10.1 Global Biologics and Biosimilars Forecast by Regions (2025-2030)
10.1.1 Global Biologics and Biosimilars Forecast by Regions (2025-2030)
10.1.2 Americas Biologics and Biosimilars Forecast
10.1.3 APAC Biologics and Biosimilars Forecast
10.1.4 Europe Biologics and Biosimilars Forecast
10.1.5 Middle East & Africa Biologics and Biosimilars Forecast
10.2 Americas Biologics and Biosimilars Forecast by Country (2025-2030)
10.2.1 United States Biologics and Biosimilars 麻豆原创 Forecast
10.2.2 Canada Biologics and Biosimilars 麻豆原创 Forecast
10.2.3 Mexico Biologics and Biosimilars 麻豆原创 Forecast
10.2.4 Brazil Biologics and Biosimilars 麻豆原创 Forecast
10.3 APAC Biologics and Biosimilars Forecast by Region (2025-2030)
10.3.1 China Biologics and Biosimilars 麻豆原创 Forecast
10.3.2 Japan Biologics and Biosimilars 麻豆原创 Forecast
10.3.3 Korea Biologics and Biosimilars 麻豆原创 Forecast
10.3.4 Southeast Asia Biologics and Biosimilars 麻豆原创 Forecast
10.3.5 India Biologics and Biosimilars 麻豆原创 Forecast
10.3.6 Australia Biologics and Biosimilars 麻豆原创 Forecast
10.4 Europe Biologics and Biosimilars Forecast by Country (2025-2030)
10.4.1 Germany Biologics and Biosimilars 麻豆原创 Forecast
10.4.2 France Biologics and Biosimilars 麻豆原创 Forecast
10.4.3 UK Biologics and Biosimilars 麻豆原创 Forecast
10.4.4 Italy Biologics and Biosimilars 麻豆原创 Forecast
10.4.5 Russia Biologics and Biosimilars 麻豆原创 Forecast
10.5 Middle East & Africa Biologics and Biosimilars Forecast by Region (2025-2030)
10.5.1 Egypt Biologics and Biosimilars 麻豆原创 Forecast
10.5.2 South Africa Biologics and Biosimilars 麻豆原创 Forecast
10.5.3 Israel Biologics and Biosimilars 麻豆原创 Forecast
10.5.4 Turkey Biologics and Biosimilars 麻豆原创 Forecast
10.5.5 GCC Countries Biologics and Biosimilars 麻豆原创 Forecast
10.6 Global Biologics and Biosimilars Forecast by Type (2025-2030)
10.7 Global Biologics and Biosimilars Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Biologics and Biosimilars Product Offered
11.1.3 Roche Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Amgen
11.2.1 Amgen Company Information
11.2.2 Amgen Biologics and Biosimilars Product Offered
11.2.3 Amgen Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Amgen Main Business Overview
11.2.5 Amgen Latest Developments
11.3 AbbVie
11.3.1 AbbVie Company Information
11.3.2 AbbVie Biologics and Biosimilars Product Offered
11.3.3 AbbVie Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 AbbVie Main Business Overview
11.3.5 AbbVie Latest Developments
11.4 Sanofi
11.4.1 Sanofi Company Information
11.4.2 Sanofi Biologics and Biosimilars Product Offered
11.4.3 Sanofi Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Sanofi Main Business Overview
11.4.5 Sanofi Latest Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Information
11.5.2 Johnson & Johnson Biologics and Biosimilars Product Offered
11.5.3 Johnson & Johnson Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Johnson & Johnson Main Business Overview
11.5.5 Johnson & Johnson Latest Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer Biologics and Biosimilars Product Offered
11.6.3 Pfizer Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Pfizer Main Business Overview
11.6.5 Pfizer Latest Developments
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Information
11.7.2 Novo Nordisk Biologics and Biosimilars Product Offered
11.7.3 Novo Nordisk Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Novo Nordisk Main Business Overview
11.7.5 Novo Nordisk Latest Developments
11.8 Eli Lilly
11.8.1 Eli Lilly Company Information
11.8.2 Eli Lilly Biologics and Biosimilars Product Offered
11.8.3 Eli Lilly Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Eli Lilly Main Business Overview
11.8.5 Eli Lilly Latest Developments
11.9 Novartis
11.9.1 Novartis Company Information
11.9.2 Novartis Biologics and Biosimilars Product Offered
11.9.3 Novartis Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Novartis Main Business Overview
11.9.5 Novartis Latest Developments
11.10 Merck
11.10.1 Merck Company Information
11.10.2 Merck Biologics and Biosimilars Product Offered
11.10.3 Merck Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Merck Main Business Overview
11.10.5 Merck Latest Developments
11.11 Biogen
11.11.1 Biogen Company Information
11.11.2 Biogen Biologics and Biosimilars Product Offered
11.11.3 Biogen Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Biogen Main Business Overview
11.11.5 Biogen Latest Developments
11.12 Celltrion
11.12.1 Celltrion Company Information
11.12.2 Celltrion Biologics and Biosimilars Product Offered
11.12.3 Celltrion Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Celltrion Main Business Overview
11.12.5 Celltrion Latest Developments
11.13 Sobi
11.13.1 Sobi Company Information
11.13.2 Sobi Biologics and Biosimilars Product Offered
11.13.3 Sobi Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Sobi Main Business Overview
11.13.5 Sobi Latest Developments
11.14 3SBIO
11.14.1 3SBIO Company Information
11.14.2 3SBIO Biologics and Biosimilars Product Offered
11.14.3 3SBIO Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 3SBIO Main Business Overview
11.14.5 3SBIO Latest Developments
11.15 Changchun High Tech
11.15.1 Changchun High Tech Company Information
11.15.2 Changchun High Tech Biologics and Biosimilars Product Offered
11.15.3 Changchun High Tech Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 Changchun High Tech Main Business Overview
11.15.5 Changchun High Tech Latest Developments
11.16 Kanghong Pharma
11.16.1 Kanghong Pharma Company Information
11.16.2 Kanghong Pharma Biologics and Biosimilars Product Offered
11.16.3 Kanghong Pharma Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 Kanghong Pharma Main Business Overview
11.16.5 Kanghong Pharma Latest Developments
11.17 Innovent Biologics
11.17.1 Innovent Biologics Company Information
11.17.2 Innovent Biologics Biologics and Biosimilars Product Offered
11.17.3 Innovent Biologics Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.17.4 Innovent Biologics Main Business Overview
11.17.5 Innovent Biologics Latest Developments
11.18 Gan&Lee
11.18.1 Gan&Lee Company Information
11.18.2 Gan&Lee Biologics and Biosimilars Product Offered
11.18.3 Gan&Lee Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.18.4 Gan&Lee Main Business Overview
11.18.5 Gan&Lee Latest Developments
11.19 Tonghua Dongbao
11.19.1 Tonghua Dongbao Company Information
11.19.2 Tonghua Dongbao Biologics and Biosimilars Product Offered
11.19.3 Tonghua Dongbao Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.19.4 Tonghua Dongbao Main Business Overview
11.19.5 Tonghua Dongbao Latest Developments
11.20 United Laboratory
11.20.1 United Laboratory Company Information
11.20.2 United Laboratory Biologics and Biosimilars Product Offered
11.20.3 United Laboratory Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.20.4 United Laboratory Main Business Overview
11.20.5 United Laboratory Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.